Drug Profile
Del-1 gene therapy - Indevus Pharmaceuticals
Latest Information Update: 13 Jul 1999
Price :
$50
*
At a glance
- Originator Indevus Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders
Most Recent Events
- 13 Jul 1999 Del-1 gene therapy - Progenitor is now called Del-1 gene therapy - Interneuron
- 13 Jul 1999 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 13 Jul 1999 Discontinued-Preclinical for Cardiovascular disorders in USA (Unknown route)